The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Regulatory News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of Meeting

9 Mar 2020 11:07

RNS Number : 4455F
4d Pharma PLC
09 March 2020
 

4D pharma plc

 

("4D pharma" or the "Company")

 

Result of General Meeting

 

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutic products, announces that, at the General Meeting held earlier today to enable the proposed issue of a total of 44,000,000 New Ordinary Shares in connection with the Placing and Subscription to raise gross proceeds of £22 million, all Resolutions were duly passed.

 

Further to the Result of Placing announcement made on 18 February 2020, 27,176,920 Subscription Shares and 16,823,080 Placing Shares will be issued. The total number of New Ordinary Shares to be issued pursuant to the Subscription and Placing remains unchanged.

Application has been made to the London Stock Exchange for the 44,000,000 New Ordinary Shares to be admitted to trading on AIM and it is expected that Admission will occur and dealings commence at 8.00 a.m. tomorrow, 10 March 2020.

Total Voting Rights

Following Admission, the Company will have 109,493,842 Ordinary Shares in issue. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. There Company holds no Ordinary Shares in treasury.

Block Admission

A block admission has been made in respect of 22,000,000 shares which may arise from the exercise of Warrants issued in connection with the Fundraising ("Warrant Shares") under the scheme name '4D March 2020 Warrants'. Admission of the block listed shares will also take effect on 10 March 2020. For the avoidance of doubt, the Warrants themselves will not be admitted to Trading on AIM. Each Warrant entitles the holder to subscribe for one Ordinary Share at a price of 100 pence at any time up to 10 March 2025.

 

Definitions

 

Capitalised terms used in this announcement shall, unless defined in this announcement or unless the context provides otherwise, bear the same meaning ascribed to them in the announcement made by the Company on 18 February 2020 to announce the launch of the Placing.

 

 

For further information please contact:

4D

 

Duncan Peyton, Chief Executive Officer

ir@4dpharmaplc.com

+ 44 (0)113 895 0130

 

 

N+1 Singer - Nominated Adviser, Joint Bookrunner and Joint Broker

+44 (0) 20 7496 3000

Aubrey Powell / Justin McKeegan / Alex Bond (Corporate Finance)

Tom Salvesen (Corporate Broking)

 

 

Bryan Garnier & Co. Limited - Joint Bookrunner and Joint Broker

+44 (0)20 7332 2500

Dominic Wilson / Phil Walker

 

Chardan - US Placing Agent

David Lederman (Equity Capital Markets)

+1 646 465-9011

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ROMJLMBTMTMMBFM
Date   Source Headline
21st Dec 20187:00 amRNSDirector/PDMR Shareholding
19th Dec 20187:00 amRNSDirector/PDMR Shareholding
13th Dec 20187:00 amRNSPDMR Dealings
12th Dec 20184:40 pmRNSSecond Price Monitoring Extn
12th Dec 20184:35 pmRNSPrice Monitoring Extension
12th Dec 20187:00 amRNSTrading Statement
8th Nov 20187:00 amRNSClinical Update - Blautix Phase II study
8th Nov 20187:00 amGNW4D pharma plc Announces Clinical Update for Blautix Phase II Study
28th Sep 20187:00 amRNSInterim results
24th Sep 20187:00 amRNSClinical update and publication of studies
14th Aug 20187:00 amRNS4D asthma publication
30th Jul 20187:00 amRNSPublication - microbiota as HDAC inhibitors
27th Jun 20187:00 amRNS4D Presents at IHMC 2018
25th Jun 20184:40 pmRNSSecond Price Monitoring Extn
25th Jun 20184:35 pmRNSPrice Monitoring Extension
13th Jun 20187:00 amRNSMHRA and HPRA clear Blautix Phase II study
12th Jun 20184:51 pmRNSHolding(s) in Company
7th Jun 20187:00 amRNSClinical Collaboration Agreement
4th Jun 20187:00 amRNS4D Presents Phase Ib Clinical Data on Blautix
21st May 201812:08 pmRNSResult of AGM
21st May 20187:00 amRNSMRx0518 - Monotherapy trial approved
8th May 20187:00 amRNSClinical Update - Blautix IND
26th Apr 20187:00 amRNSAnnual Report and Notice of AGM
23rd Apr 20187:00 amRNSFinal Results
21st Mar 20187:00 amRNSOncology candidate update
20th Feb 20187:00 amRNSAppointment of Joint Broker
28th Sep 20177:00 amRNSInterim results
5th Sep 201712:54 pmRNSHolding(s) in Company
24th Aug 20177:00 amRNSIssue of Equity
26th May 20171:59 pmRNSResult of AGM
17th May 20174:40 pmRNSSecond Price Monitoring Extn
17th May 20174:35 pmRNSPrice Monitoring Extension
3rd May 20177:00 amRNSAnnual Report and Notice of AGM
27th Apr 20177:00 amRNSFinal Results
18th Apr 20177:59 amRNSAppointment of Joint Broker
10th Mar 20174:37 pmRNSHolding(s) in Company
6th Mar 20177:00 amRNSClinical Update
13th Dec 20167:00 amRNSClinical Update
9th Nov 20164:40 pmRNSSecond Price Monitoring Extn
9th Nov 20164:35 pmRNSPrice Monitoring Extension
8th Nov 20164:40 pmRNSSecond Price Monitoring Extn
8th Nov 20164:35 pmRNSPrice Monitoring Extension
19th Oct 20164:40 pmRNSSecond Price Monitoring Extn
19th Oct 20164:35 pmRNSPrice Monitoring Extension
30th Sep 20167:00 amRNSInterim results for the period ended 30 June 2016
27th Sep 201610:59 amRNSHolding(s) in Company
15th Sep 20164:40 pmRNSSecond Price Monitoring Extn
15th Sep 20164:35 pmRNSPrice Monitoring Extension
9th Sep 201611:58 amRNSHolding(s) in Company
22nd Aug 20167:00 amRNSClinical Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.